NST 141

Drug Profile

NST 141

Alternative Names: NS-141; NST141

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Nippon Shinyaku
  • Class Anti-inflammatories; Skin disorder therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pruritus

Most Recent Events

  • 12 Mar 2012 Phase II development is ongoing in Japan
  • 09 Mar 2012 NST 141 is no longer licensed to Taiho Pharmaceutical in Japan
  • 31 May 2009 Phase-I clinical trials in Pruritus in Japan (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top